Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER) Meeting Abstract
| Authors: | Strickler, J. H.; Cercek, A.; Siena, S.; Andre, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J. M.; Coveler, A. L.; Fountzilas, C.; Kardosh, A.; Kasi, P. M.; Lenz, H. J.; Ciombor, K. K.; Elez, E.; Bajor, D. L.; Nayeri, M.; Feng, W.; Bekaii-Saab, T. S. |
| Abstract Title: | Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400768 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.3509 |
| Notes: | Meeting Abstract: 3509 -- Source: Wos |
